Related Experiment Video

Updated: Aug 21, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy

Julia Glade Bender1, Erin M Cooney, Jessica J Kandel

  • 1Division of Pediatric Oncology, College of Physicians and Surgeons at Columbia University, Irving Pavilion 7, 161 Fort Washington Avenue, New York, NY 10032, USA.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|November 10, 2004
PubMed

Insights

Antiangiogenic therapy shows promise but faces resistance. Researchers are identifying factors like PDGF-B and angiopoietin-1 involved in vascular remodeling to improve cancer treatment efficacy.

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Therapeutics

Background:

  • Antiangiogenic therapy, particularly targeting the vascular endothelial growth factor (VEGF) pathway, was initially envisioned for universal cancer treatment efficacy with low toxicity and minimal resistance.
  • VEGF pathway blockade has demonstrated significant promise in both preclinical models and clinical settings for cancer therapy.

Purpose of the Study:

  • To investigate the mechanisms of resistance to antiangiogenic therapy, specifically VEGF blockade, in cancer treatment.
  • To identify factors contributing to vascular remodeling that may mediate resistance to antiangiogenic agents.

Main Methods:

  • Review of existing literature on antiangiogenic therapy and resistance mechanisms.
  • Analysis of studies involving VEGF blockade in combination with chemotherapy or other antiangiogenic agents.
  • Examination of the role of vascular remodeling and specific angiogenic factors in treatment resistance.

Main Results:

  • Resistance to VEGF blockade is observed, even when used in combination therapies.
  • Vascular remodeling and increased expression of factors like platelet-derived growth factor B (PDGF-B) and angiopoietin-1 are associated with this resistance.
  • These factors may play a role in stabilizing tumor vasculature, counteracting antiangiogenic effects.

Conclusions:

  • Resistance to antiangiogenic therapy is a significant challenge in cancer treatment.
  • Understanding the factors driving vascular remodeling is crucial for overcoming resistance.
  • Future research should focus on identifying and targeting these factors to enhance the efficacy of antiangiogenic strategies.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Vascular Resistance01:20

Vascular Resistance

Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...